Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

Diabetes, Obesity and Metabolism

Volumn 12, Issue 8, 2010, Pages 648-658

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Alogliptin; DPP 4 inhibitor; Linagliptin; Pharmacokinetics; Saxagliptin; Sitagliptin; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; ALOGLIPTIN; BMS 510849; CYTOCHROME P450; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG METABOLITE; KETOCONAZOLE; LINAGLIPTIN; METFORMIN; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; ENZYME INACTIVATION; FOOD INTAKE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW; URINARY EXCRETION;

EID: 77955456705     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01212.x     Document Type: Review

References (76)

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
3. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997; 54: 355-368.
4. Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998; 55: 225-236.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
6. Scheen AJ. Current management of coexisting obesity and type 2 diabetes. Drugs 2003; 63: 1165-1184.
7. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Safety 2005; 28: 601-631.
8. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007; 46: 93-108.
9. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
10. Idris S, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diab Obes Metab 2007; 9: 153-165.
11. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; Issue 2, Art. No.: CD006739.
12. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009; 49 (Suppl. 1): S16-S29.
13. Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009; 23: 487-498.
14. Lyseng-Williamson KA. Sitagliptin. Drugs 2007; 67: 587-597.
15. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 2007; 29: 2614-2634.
16. Henness S, Keam SJ. Vildagliptin. Drugs 2006; 66: 1989-2001.
17. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008; 68: 2387-2409.
18. Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs 2008; 11: 906-917.
19. Cole P, Serradell N, Bolos R, Castaner R. Saxagliptin. Drugs Future 2008; 33: 577-586.
20. Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2008; 9: 402-413.
21. Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009; 10: 503-512.
22. Rungby J. Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes. Exp Opin Invest Drugs 2009; 18: 835-838.
23. Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr Opin Invest Drugs 2009; 10: 1091-1104.
24. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010 (in press).
25. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf. Accessed 28 September 2007.
26. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-en6.pdf. Accessed 29 July 2008.
27. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/onglyza/H-1039-fr1.pdf
28. Reynolds JK, Neumiller JJ, Campbell RK. Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert Opin Invest Drugs 2008; 17: 1559-1565.
29. Vincent SH, Reed JR, Bergman AJ et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007; 35: 533-538.
30. Bergman A, Ebel D, Liu F et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007; 28: 315-322.
31. Chu XY, Bleasby K, Yabut J et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007; 321: 673-683.
32. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-688.
33. Bergman A, Mistry GC, Luo WL et al. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007; 28: 307-313.
34. Bergman AJ, Stevens C, Zhou Y et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
35. Herman GA, Bergman A, Liu F et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006; 46: 876-886.
36. Bergman A, Stevens C, Yi B et al. Lack of a clinically meaningful effect of age, gender or obesity on the pharmacokinetics of the DPP-IV inhibitor MK-0431 (Abstract 2101-PO). Diabetes 2005; 54 (Suppl. 1): A506.
37. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
38. Bergman AJ, Cote J, Yi B et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862-1864.
39. Chan JC, Scott R, Arjona Ferreira JC et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10: 545-555.
40. Migoya EM, Stevens CH, Bergman AJ et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009; 16: e165-e170.
41. Banerjee M, Younis N, Soran H. Vildagliptin in clinical practice: a review of the literature. Expert Opin Pharmacother 2009; 10: 2745-2757.
42. Tahrani AA, Piya MK, Barnett AH. Drug evaluation: vildagliptin-metformin single-tablet combination. Adv Ther 2009; 26: 138-154.
43. He H, Tran P, Yin H et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37: 536-544.
44. He YL, Sadler BM, Sabo R et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007; 46: 787-802.
45. He YL,Sabo R,Campestrini J et al. The effec to fage, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 2008; 65: 338-346.
46. Sunkara G, Sabo R, Wang Y et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007; 47: 1152-1158.
47. He YL, Flannery B, Campestrini J et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 2008; 24: 1703-1709.
48. Hu P, Yin Q, Deckert F et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009; 49: 39-49.
49. He YL, Sabo R, Picard F et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 1265-1272.
50. He YL, Flannery B, Wang Y et al. The influence of renal impairment on pharmacokinetics of vildagliptin (Abstract PIII-86). Clin Pharmacol Ther 2007; 81 (Suppl. 1): S113.
51. Thuren T, Byiers S, Mohideen P, Goodman M. Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment (Abstract OP 74). Diabetologia 2008; 51 (Suppl. 1): S36.
52. He YL, Sabo R, Campestrini J et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007; 63: 677-686.
53. Kothny W, Schweizer A, Dickinson S, Ligueros-Saylan M. Hepatic safety profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes (abstract). Diabetologia 2009; 52 (Suppl. 1): S301.
54. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009; 26: 249-262.
55. Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009; 26: 488-499.
56. Dhillon S, Weber J. Saxagliptin. Drugs 2009; 69: 2105-2114.
57. Fura A, Khanna A, Vyas V et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009; 37: 1164-1171.
58. Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects (Abstract 606-P). Diabetes 2007; 56 (Suppl. 1): A161.
59. Boulton DW, Goyal A, LiL, Kornhauser DM, Frevert U. The effects of age and gender on the single dose pharmacokinetics and safety of saxagliptin in healthy subjects (Abstract 551-P). Diabetes 2008; 57 (Suppl. 1): A164.
60. Boulton D, Tang A, Patel C et al. Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment. Endocrine Abstracts 2009; 20: P357.
61. Patel C, Castaneda L, Frevert U, Li L, Kornhauser DM, Boulton DW. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects (Abstract 537-P). Diabetes 2008; 57 (Suppl. 1): A160.
62. Christopher A, Karim A. Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes. Exp Rev Clin Pharmacol 2009; 2: 589-600.
63. Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ. Pharma-cokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 2008; 589: 306-314.
64. Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008; 30: 513-527.
65. Karim A, Covington P, Christopher R et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010; 48: 46-58.
66. Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009; 49: 1210-1219.
67. Covington P, Christopher R, Davenport M et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008; 30: 499-512.
68. Karim A, Fleck P, Hetman L et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment (Abstract 538-P). Diabetes 2008; 57 (Suppl. 1): A160.
69. Karim A, Fleck P, Dorsey D et al. Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment (Abstract). J Clin Pharmacol 2007; 47: Abstract 107.
70. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Exp Opin Invest Drugs 2010; 19: 133-140.
71. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009; 61: 55-62.
72. Fuchs H., Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009; 30: 229-240.
73. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidylpeptidase 4, in healthy male volunteers. J Clin Pharmacol 2008; 48: 1171-1178.
74. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009; 25: 1963-1972.
75. Blech S, Ludwig-Schwellinger E, Graefe-Mody UE, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; Jan 19 [Epub ahead of print].
76. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser S, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009; 11: 786-794.